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a  b  s  t  r  a  c  t
Among  more  than  2500  nontyphoidal  Salmonella  enterica  (NTS)  serovars,  S. enterica  serovar  Typhimurium
and  S. enterica  serovar  Enteritidis  account  for  approximately  ﬁfty  percent  of all  human  isolates  of NTS
reported  globally.  The  global  incidence  of  NTS gastroenteritis  in 2010  was  estimated  to be 93 million
cases,  approximately  80  million  of which  were  contracted  via  food-borne  transmission.  It  is estimated
that  155,000  deaths  resulted  from  NTS  in  2010.  NTS  also  causes  severe,  extra-intestinal,  invasive  bac-
teremia,  referred  to  as invasive  nontyphoidal  Salmonella  (iNTS)  disease.  iNTS  disease  usually  presents  as
a febrile  illness,  frequently  without  gastrointestinal  symptoms,  in both  adults  and children.  Symptoms  of
iNTS  are similar  to malaria,  often  including  fever  (>90%)  and splenomegaly  (>40%).  The  underlying  reasons
for the high  rates  of  iNTS  disease  in  Africa  are  still  being  elucidated.  Evidence  from  animal  and  human
studies  supports  the feasibility  of developing  a  safe  and  effective  vaccine  against  iNTS.  Both antibodies  and
complement  can  kill  Salmonella  species  in  vitro.  Proof-of-principle  studies  in  animal  models  have  demon-
strated  efﬁcacy  for  live  attenuated  and subunit  vaccines  that  target  the  O-antigens,  ﬂagellin  proteins,  and
other outer  membrane  proteins  of serovars  Typhimurium  and  Enteritidis.  More recently,  a  novel delivery
strategy  for  NTS  vaccines  has  been  developed:  the  Generalized  Modules  for Membrane  Antigens  (GMMA)
technology  which  presents  surface  polysaccharides  and  outer  membrane  proteins  in  their  native  con-
formation.  GMMA  technology  is  self-adjuvanting,  as  it delivers  multiple  pathogen-associated  molecular
pattern  molecules.  GMMA  may  be particularly  relevant  for low-  and  middle-income  countries  as  it  has
the potential  for high  immunologic  potency  at a low  cost  and  involves  a relatively  simple  production
process  without  the  need  for complex  conjugation.  Several  vaccines  for the  predominant  NTS  serovars
Typhimurium  and Enteritidis,  are  currently  under  development.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).
The genus Salmonella belongs to the Enterobacteriaceae fam-
ily and comprises Gram-negative, non-spore-forming, facultative
anaerobic bacilli [1]. Salmonella enterica subspecies enterica serovar
Typhi and Salmonella Paratyphi A and B cause enteric fever, a sys-
temic febrile illness that only occurs in humans and is distinguished
from the more common self-limited acute gastroenteritis caused by
other Salmonella serotypes. Non-typhoidal Salmonella (NTS) infect
a variety of hosts and are frequently zoonotic in origin [2]. Of
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the more than 2,500 NTS serovars, Salmonella Typhimurium and
Salmonella Enteritidis account for approximately 50% of all human
isolates of NTS reported globally. NTS has been recognized as a
major cause of invasive bacterial infections in young children and
HIV-infected individuals in sub-Saharan Africa as well as elderly
and immunocompromised individuals worldwide [3,4].
The global incidence of NTS gastroenteritis was estimated to
be 93 million cases in 2010; approximately 80 million contracted
the infection via food-borne transmission [3]. It is estimated that
155,000 deaths resulted from NTS that year. NTS also causes severe,
extra-intestinal, invasive bacteremia, referred to as invasive non-
typhoidal Salmonella (iNTS) disease [2]. A recent estimate suggests
that, globally, there are 49 cases (range of 30–94) of iNTS per
http://dx.doi.org/10.1016/j.vaccine.2016.03.072
0264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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100,000 population which means that 3.4 (range 2.1–6.5) million
cases occur globally each year [5]. In Africa, the iNTS incidence
is much higher (227 [range of 142–341] cases per 100,000). iNTS
disease usually presents as a febrile illness, frequently without gas-
trointestinal symptoms, in both adults and children. Symptoms
of iNTS are similar to malaria, often including fever (>90%) and
splenomegaly (>40%). The underlying reason for the high rates of
iNTS disease in Africa are still being elucidated; however, there
are several established contributing factors that include increased
invasiveness of distinct clades speciﬁc to Africa (e.g. Salmonella
Typhimurium ST313), compromised host immunity in those with
HIV infection, malaria, malnutrition, and increased opportunities
for transmission (e.g., through contaminated water supplies). NTS
bacteremia is particularly virulent in HIV-infected African adults
who have a mortality rate of 47 per cent and recurrence rate of 43
per cent [6]. As a whole, the iNTS case fatality rate is estimated to
be ∼20% translating into 681,316 (range of 415,164 to 1,301,520)
deaths annually [5]. Although mortality is lower in high income
countries, the economic burden of NTS in those countries is still
signiﬁcant. In the United States, NTS costs US$3.3 billion per year,
with a loss of 17,000 quality-adjusted life years, the most of any
food-borne pathogen [3]. iNTS disease has been overshadowed in
the past by other diseases for which better data available, such as
malaria, and HIV. The gaps in knowledge about the epidemiology
of iNTS, however, are starting to close.
Because the typical clinical presentation of iNTS disease is non-
speciﬁc, diagnosis is often difﬁcult in resource-limited settings.
Blood or bone-marrow culture may  be used to diagnose cases of
bacteremia. Polymerase chain reaction (PCR) on stool samples can
potentially aid in the rapid diagnosis of Salmonella and multiplex
PCR may  serve as a means to identify speciﬁc invasive Salmonella
serovars [7]. Serum ELISA is helpful in detecting past Salmonella
infections, but is less useful for iNTS diagnosis for acute infections
[8]. iNTS disease is primarily treated with antibiotics, whose class
and duration are chosen on the basis of cost, availability, local pat-
terns of resistance and treatment response. Treatment failure is of
increasing concern in HIV-infected individuals and those infected
with antibiotic-resistant strains (e.g. ST313). One approach toward
overcoming these obstacles is to treat people with antibiotics that
have optimal intracellular penetration, such as ﬂuoroquinolones
[9], although resistance to this class of antibiotics is increasing
as well. The global burden of iNTS disease is likely to continue
rising in absolute numbers and in the relative proportion of bac-
teremia cases, particularly as antimicrobial resistance becomes
more prevalent and licensed vaccines reduce the incidence of other
major causes of bacteremia, such as Streptococcus pneumoniae and
Haemophilus inﬂuenzae b. As available tools for treatment become
less effective, the development of effective vaccines will rise in
priority for disease control efforts [2].
1. Biological feasibility for vaccine development
Effective Salmonella Typhi vaccines have been successfully
licensed and administered to millions of people. Evidence from
animal and human studies supports the feasibility of vaccine devel-
opment against NTS as well. Both antibodies and complement
can kill Salmonella species in vitro. Epidemiologic studies in sub-
Saharan Africa have shown that the development of antibodies
against NTS corresponds with a decrease in age-related incidence
of iNTS disease, and that serum antibodies have correspond-
ing in vitro bactericidal activity partly by mediating intracellular
oxidation [9,10]. However, one African study found that high anti-
body titers against Salmonella lipopolysaccharide (LPS) O-antigen
were associated with impaired in vitro serum killing of Salmonella
Typhimurium in a proportion of HIV-infected Malawian adults [10].
The in vivo signiﬁcance of this observation is not clear, as anti-
LPS antibodies have bactericidal activity, protecting against NTS
challenge in mouse models [9,10].
2. General approaches to vaccine development for low- and
middle-income markets
Proof-of-principle studies have demonstrated efﬁcacy, in ani-
mal  models, of live-attenuated and subunit vaccines that target
the O-antigens, ﬂagellin proteins, and other outer membrane pro-
teins of Salmonella Typhimurium and Salmonella Enteritidis. The
relatively poor immunogenicity of puriﬁed O-antigens can be
signiﬁcantly enhanced through chemical linkage to carrier pro-
teins. The subunit glycoconjugation approach speciﬁcally links
LPS-derived O polysaccharide to carrier proteins and has been
successful as, unlike Salmonella Typhi, the NTS are not encapsu-
lated. More recently, a novel delivery strategy for NTS vaccines has
been developed: the Generalized Modules for Membrane Antigens
(GMMA) technology presents surface polysaccharides and outer
membrane proteins in their native conformation. GMMA  technol-
ogy is self-adjuvanting, as it delivers multiple pathogen-associated
molecular pattern molecules. GMMA  may  be particularly relevant
for low- and middle-income countries as it has the potential for
high immunologic potency at a low cost and involves a relatively
simple production process without the need for complex conjuga-
tion.
The development of recombinant or puriﬁed protein vaccines
based on surface or outer membrane protein antigens, such as
ﬂagellin and porins OmpC, F and D offer the potential for broad-
spectrum coverage due to targeting of conserved antigens. A
reverse vaccinology approach using bioinformatics analysis of
whole genome sequences from clinically important serovars may
facilitate identiﬁcation of additional conserved antigens. However,
manufacturing complexities in purifying outer membrane proteins
with the appropriate conformation may  obviate the utility of porins
as immunogens. Other promising vaccine approaches against iNTS
disease include live attenuated candidates, which can be delivered
orally and induce robust mucosal and T cell immunity.
Vaccines for iNTS will also need to target 2-4 month old infants,
before the peak incidence at age 12 months. Programmatic ﬁeld
implementation in children could integrate directly with existing
Expanded Program on Immunization schedules, potentially at 6,
10, and 14 weeks, or at 9 months concomitant with measles vac-
cination. This schedule will allow for programmatic introduction,
as well as will enable children to be protected at an earlier age
when they are at higher risk of disease. Vaccine implementation
would likely also include populations infected with HIV. In higher
income countries, NTS vaccines could also target the elderly who
experience a high case-fatality rate of up to 50%.
3. Technical and regulatory assessment
In 2013, the World Health Organization provided guidance on
the regulation and prequaliﬁcation of typhoid conjugate vaccines
[11] [12]. Although no such pathway is available for NTS vaccines,
the experience with typhoid vaccines may  serve as a good model to
adapt. There are relatively robust animal models that can be used
to evaluate preclinical data. Mice, for example, are permissive to
Salmonella Typhimurium and Salmonella Enteritidis systemic infec-
tion that begins via entry through the gut mucosa and spreads
through the lymphatic system. In untreated mice, infection mani-
fests as invasive disease without gastroenteritis. To produce an NTS
enterocolitis infection, mice must be pre-treated with streptomycin
or other antibiotics prior to bacterial challenge. There are impor-
tant differences to consider between mouse and human infections,
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Table  1
Development status of current nontyphoidal Salmonella vaccine candidates (POC = proof-of-concept trial).
Candidate name/identiﬁer Preclinical Phase I Phase II POC Phase III
CVD 1931 (Salmonella Typhimurium guaBA clpX)  and CVD
1944 (Salmonella Enteritidis R11 guaBA clpX), live oral [UMB]
X
Bivalent COPS: FliC O:1,4[5],12:H:i + O:1,9,12:H:g,m conjugates
using CVD 1925 and CVD 1943 reagent strains [UMB; Bharat
Biotech; Wellcome Trust]
X
Bivalent iNTS-GMMA [NVGH] X
Bivalent conjugate (O:1,4[5],12-CRM197 + O:1,9,12-CRM197)
[NVGH]
X
OmpD [University of Birmingham] X
O:4,12-TT [NIH] X
WTO5 [Microscience Limited] X
such as the inability of mouse complement to kill NTS in vitro
[12]. Although immunologic correlates of protection have not yet
been identiﬁed, data from Malawi have shown that acquisition of
circulating antibodies to Salmonella Typhimurium, including the
surface lipopolysaccharide, is associated with a lower risk of NTS
bacteremia, particularly in the ﬁrst few months of life when mater-
nal antibodies are still present [10]. In vitro assays are available to
quantify the serum bactericidal activity (SBA) of antibodies induced
by Salmonella Typhimurium and Salmonella Enteritidis infection
[15] and to assess the opsonophagocytic killing activity of anti-
Salmonella antibodies [8].
4. Status of vaccine R&D activities
Several vaccines for Salmonella Typhimurium and Salmonella
Enteritidis are under development, some of which are bivalent
for both serovars (Table 1). It is unclear if these vaccine candi-
dates will be protective against both gastroenteritis and invasive
disease, but it has been proposed that a multivalent vaccine that
targets 5–6 serovars could protect against the most relevant forms
of gastroenteritis and invasive Salmonella worldwide [13,14]. The
Center for Vaccine Development at the University of Maryland,
Baltimore (UMB) is developing live-attenuated, oral vaccines for
both Salmonella Typhimurium (CVD 1931, derived from a wild-type
Salmonella Typhimurium strain from the ST313 genotype circulat-
ing in sub-Saharan Africa) and Salmonella Enteritidis (CVD 1944,
derived from wild-type invasive Salmonella Enteritidis). These
attenuated strains induce seroconversion (four-fold or greater anti-
body titer rise) of functional anti-LPS and anti-ﬂagellin antibodies
and are also expected to elicit robust cell-mediated immunity, a
key component required for the resolution of Salmonella infec-
tions. Furthermore, CVD 1921, a prototype attenuated Salmonella
Typhimurium vaccine strain, has been shown to be safe and well-
tolerated in immunocompromised non-human primates [15].
Microscience Limited has published results from the only live
attenuated NTS vaccine candidate to be tested in humans. The vac-
cine, WT05, is derived from a gastroenteritis-associated strain of
Salmonella Typhimurium and is attenuated by deletion of the aroC
and the ssaV genes. A Phase 1 clinical trial of this product found
there to be prolonged stool shedding of the vaccine strain in healthy
volunteers for up to 23 days. In 1992, the US National Institutes
of Health (NIH) published pre-clinical research on an NTS conju-
gate vaccine for Salmonella Typhimurium that linked O:4 to tetanus
toxoid (O:4-TT) [16]. This O:4-TT conjugate vaccine was  able to
protect mice against lethal challenge with wild-type Salmonella
Typhimurium.
UMB  has developed a bivalent, NTS conjugate vaccine candidate
that covalently links the core and O-polysaccharides (COPS; both
core and O polysaccharide are components of LPS) of Salmonella
Typhimurium and Salmonella Enteritidis to the homologous Phase
1 ﬂagellin subunits, respectively. It is hypothesized that by using
a Salmonella protective protein antigen instead of a heterologous
pathogen protein (e.g., tetanus toxoid, CRM197), enhanced efﬁ-
cacy may  be achieved as antibodies would be directed towards two
independent protective targets on the bacterial surface. It has been
shown that ﬂagellin elicits a robust antibody response and that ﬂag-
ellin alone is protective in a mouse model of invasive NTS infection.
UMB has created reagent strains of Salmonella Typhimurium and
Salmonella Enteritidis that hyper-express ﬂagellin that are valu-
able for the economical and safe puriﬁcation of components for the
NTS COPS-FliC conjugate vaccines. UMB  has also developed high-
yield, low-cost methods to biochemically purify COPS and ﬂagellin
from liquid growth cultures of these strains. Salmonella Enteritidis
COPS-FliC conjugates were able to elicit protective antibodies in
preclinical studies with both components of the conjugate eliciting
Salmonella-speciﬁc immunity and protection maintained at very
low vaccine doses [14]. This vaccine is being advanced in partner-
ship with Bharat Biotech of India and the Wellcome Trust.
The Novartis Vaccines Institute for Global Health (NVGH, a GSK
company) has also developed a bivalent O-antigen polysaccharide-
CRM197 conjugate vaccine targeting both Salmonella Typhimurium
and Salmonella Enteritidis [17]. The institute’s current efforts are
focused on the advancement of the GMMA  platform for Gram-
negative bacteria, including NTS vaccine production. Bacterial
genetic modiﬁcations are introduced into Salmonella Typhimurium
and Salmonella Enteritidis parent strains to increase membrane
blebbing of small (50–90 nm)  immunogenic particles and to detox-
ify lipid A. In mice, NTS GMMA  vaccines are at least as immunogenic
at comparable doses of O-antigen glycoconjugate vaccines (NVGH,
unpublished data). Salmonella GMMA  reactogenicity remains to be
evaluated in humans; however, Shigella sonnei GMMA was  safe and
immunogenic in a Phase 1 trial in adults [18]. The ease of manufac-
turing GMMA  and its dose-sparing potential has inﬂuenced NVGH’s
vaccine development prioritization. The NVGH bivalent conjugate
vaccine is available for further development if the GMMA  platform
does not perform as expected.
The University of Birmingham has proposed a different protein-
based vaccine candidate consisting of outer membrane protein
D (OmpD), puriﬁed from whole bacteria [19]. Studies of porin-
deﬁcient bacteria showed that OmpD (absent in Salmonella Typhi)
is a viable target for antibody protection against iNTS. It should be
noted that several other vaccines against Salmonella Typhimurium
and Salmonella Enteritidis are available and/or under development
for use in veterinary medicine and commercial food production,
particularly in the raising of livestock and other key animal carriers,
most notably chickens.
5. Likelihood for ﬁnancing
iNTS disease has yet to be recognized as a major priority for
vaccine development either by global health policy institutions
or funding agencies, even though there is a signiﬁcant burden of
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childhood mortality associated with this disease [20]. It has been
proposed that until bacterial bloodstream infections are recognized
as a distinct cause of mortality, iNTS disease will remain a sig-
niﬁcant, but neglected, disease of developing countries. Although
typhoid conjugate vaccines were designated a priority by the GAVI
Alliance in 2008, no such steps have been taken for vaccines against
iNTS. Funding for research to date has come from the Wellcome
Trust, the Bill & Melinda Gates Foundation and NIH, but progress
through clinical development, especially large Phase 3 efﬁcacy
trials, will require funding from a variety of sources, including
vaccine-manufacturing partners in potential target markets.
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